Biodel Inc. to Present at the 2008 Citi Investment Research Global Healthcare Conference on May 22nd 2008
Interested parties may access a link to a live webcast of the corporatepresentation in the investor relations section of Biodel's website atwww.biodel.com. An archive of the presentation will be available at the samelocation.
About Biodel Inc.
Biodel Inc. is a specialty biopharmaceutical company focused on thedevelopment and commercialization of innovative treatments for endocrinedisorders, such as diabetes and osteoporosis. Biodel's product candidates aredeveloped by using VIAdel(TM) technology, which reformulates existingFDA-approved peptide drugs. The Company's lead product candidate,VIAject(TM), is an ultra rapid-acting injectable meal-time insulin indevelopment for use by patients with Type 1 or Type 2 diabetes. VIAject(TM)is currently being tested in two pivotal Phase III clinical trials. Biodel'spipeline also includes VIAtab(TM), a sublingual tablet formulation of insulinin the Phase I stage of clinical testing, and two pre-clinical osteoporosisproduct candidates. For further information regarding Biodel, please visitthe Company's website at www.biodel.com.
SOURCE Biodel Inc.
You May Also Like